

Gregory G Schwartz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8595553/gregory-g-schwartz-publications-by-citations.pdf>
Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82 papers	9,215 citations	38 h-index	90 g-index
90 ext. papers	11,356 ext. citations	11.3 avg, IF	5.47 L-index

#	Paper	IF	Citations
82	Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 285, 1711-18	27.4	1718
81	Effects of dalcetrapib in patients with a recent acute coronary syndrome. <i>New England Journal of Medicine</i> , 2012 , 367, 2089-99	59.2	1424
80	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2	1277
79	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. <i>New England Journal of Medicine</i> , 2016 , 374, 1321-31	59.2	654
78	High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. <i>Circulation</i> , 2003 , 108, 1560-6	16.7	330
77	Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. <i>American Heart Journal</i> , 2014 , 168, 682-9	4.9	303
76	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018 , 392, 1311-1320	40	208
75	Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 252-62	27.4	205
74	Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1515-25	27.4	177
73	Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. <i>American Heart Journal</i> , 2009 , 158, 896-901.e3	4.9	166
72	Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. <i>Circulation</i> , 2002 , 106, 1690-5	16.7	156
71	Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2267-75	15.1	154
70	High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. <i>European Heart Journal</i> , 2005 , 26, 890-6	9.5	150
69	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 133-144	15.1	147
68	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 618-628	18.1	120
67	Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 372-82		119
66	Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 2046-56	27.4	119

65	Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 387-396	15.1	96
64	Effect of Serial Infusions of CER-001, a Pre-High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 815-822	16.2	87
63	Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1167-1176	15.1	87
62	Effect of Alirocumab on Mortality After Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 103-112	16.7	72
61	Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , 2018 , 18, 109-115	11.5	70
60	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , 2020 , 141, 624-636	16.7	66
59	Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , 1998 , 81, 578-81	3	65
58	Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1565-1573	27.4	57
57	Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. <i>Diabetes Care</i> , 2005 , 28, 2508-13	14.6	54
56	Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. <i>Circulation</i> , 2020 , 141, 1608-1617	16.7	52
55	Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 164-168	16.2	51
54	Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. <i>Cardiovascular Drugs and Therapy</i> , 2015 , 29, 7-14	3.9	50
53	Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). <i>American Journal of Cardiology</i> , 2007 , 99, 632-5	3	49
52	Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes. <i>Circulation: Cardiovascular Genetics</i> , 2016 , 9, 340-8		47
51	PPAR- γ as a therapeutic target in cardiovascular disease: evidence and uncertainty. <i>Journal of Lipid Research</i> , 2012 , 53, 1738-54	6.3	46
50	PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 288, H1314-23	5.2	45
49	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020 , 41, 4245-4255	9.5	44
48	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. <i>Circulation</i> , 2017 , 135, 1882-1893	16.7	42

47	Metabolic response of the human heart to inotropic stimulation: in vivo phosphorus-31 studies of normal and cardiomyopathic myocardium. <i>Magnetic Resonance in Medicine</i> , 1992 , 25, 260-72	4.4	42
46	Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES. <i>Circulation</i> , 2019 , 140, 2054-2062	16.7	41
45	Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. <i>American Heart Journal</i> , 2004 , 148, e4	4.9	38
44	Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. <i>Cardiovascular Diagnosis and Therapy</i> , 2017 , 7, 45-51	2.6	35
43	Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1177-1186	15.1	33
42	Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1182-1193	15.1	31
41	Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. <i>European Heart Journal</i> , 2020 , 41, 2248-2258	9.5	29
40	Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. <i>American Heart Journal</i> , 2019 , 217, 72-83	4.9	27
39	Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2019 , 40, 2801-2809	9.5	27
38	PCSK9 Inhibitors: potential in cardiovascular therapeutics. <i>Current Cardiology Reports</i> , 2013 , 15, 345	4.2	27
37	High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. <i>American Heart Journal</i> , 2011 , 161, 993-9	4.9	26
36	Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. <i>American Heart Journal</i> , 2015 , 170, 117-22	4.9	25
35	Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. <i>Circulation</i> , 2019 , 140, 1578-1589	16.7	24
34	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2297-2308	15.1	23
33	Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. <i>Atherosclerosis</i> , 2019 , 290, 59-65	3.1	19
32	Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. <i>Cardiovascular Diabetology</i> , 2021 , 20, 13	8.7	17
31	Non-elastic deformation of myocardium in low-flow ischemia and reperfusion: ultrastructure-function relations. <i>Journal of Molecular and Cellular Cardiology</i> , 1999 , 31, 1157-69	5.8	16
30	Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , 2021 , 143, 1109-1122	16.7	16

29	Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 705-716	6.9	14
28	Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020 , 43, 1077-1084	14.6	13
27	Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e005858	5.8	13
26	New horizons for cholesterol ester transfer protein inhibitors. <i>Current Atherosclerosis Reports</i> , 2012 , 14, 41-8	6	13
25	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 421-433	15.1	13
24	Metformin prevents ischaemic ventricular fibrillation in metabolically normal pigs. <i>Diabetologia</i> , 2017 , 60, 1550-1558	10.3	12
23	Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. <i>European Heart Journal</i> , 2020 , 41, 4114-4123	9.5	12
22	Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes. <i>Diabetes and Vascular Disease Research</i> , 2018 , 15, 14-23	3.3	11
21	Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 195-204	3.9	11
20	Dalcetrapib in patients with an acute coronary syndrome. <i>New England Journal of Medicine</i> , 2013 , 368, 869-70	59.2	10
19	Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 33-43	3.9	10
18	High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome. <i>American Journal of Cardiology</i> , 2009 , 104, 46E-51E	3	9
17	Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. <i>Diabetes Care</i> , 2021 , 44, 1219-1227	14.6	9
16	Existing and emerging strategies to lower Lipoprotein(a). <i>Atherosclerosis</i> , 2022 , 349, 110-122	3.1	9
15	Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013 , 304, H861-73	5.2	8
14	Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 445-458	3.9	6
13	Evolving targets for lipid-modifying therapy. <i>EMBO Molecular Medicine</i> , 2014 , 6, 1215-30	12	6
12	Treatment With Dalcetrapib Modifies the Relationship Between High-Density Lipoprotein Cholesterol and C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2488-2490	15.1	4

11	Preoperative Use of Statins in Carotid Artery Stenting: A Systematic Review and Meta-analysis. <i>Journal of Endovascular Therapy</i> , 2018 , 25, 624-631	2.5	4
10	Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial.. <i>Lancet Diabetes and Endocrinology</i> , 2022 ,	18.1	4
9	Alirocumab after acute coronary syndrome in patients with a history of heart failure.. <i>European Heart Journal</i> , 2021 ,	9.5	4
8	Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial. <i>American Heart Journal</i> , 2020 , 221, 60-66	4.9	3
7	Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial. <i>Journal of Alzheimers Disease</i> , 2021 , 83, 1703-1715	4.3	3
6	Aldosterone Does Not Predict Cardiovascular Events Following Acute Coronary Syndrome in Patients Initially Without Heart Failure. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	2
5	Adenylyl Cyclase 9 Polymorphisms Reveal Potential Link to HDL Function and Cardiovascular Events in Multiple Pathologies: Potential Implications in Sickle Cell Disease. <i>Cardiovascular Drugs and Therapy</i> , 2015 , 29, 563-572	3.9	2
4	Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial. <i>Cardiovascular Diabetology</i> , 2021 , 20, 125	8.7	2
3	Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial". <i>Circulation</i> , 2020 , 142, e335-e336	16.7	1
2	Myocardial Infarction and Evolocumab. <i>JAMA Cardiology</i> , 2021 , 6, 1220-1221	16.2	1
1	Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial.. <i>Circulation Genomic and Precision Medicine</i> , 2022 , 101161CIRCGEN121003503	5.2	0